Currently, there is no established guidance on how to process and evaluate resected lung
cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical …

Background Neoadjuvant anti-PD-1 may improve outcomes for patients with resectable
NSCLC and provides a critical window for examining pathologic features associated with …

Introduction: We evaluated the ability of histopathologic response criteria to predict overall
survival (OS) and disease-free survival (DFS) in patients with surgically resected non-small …

Introduction We have suggested that major pathologic response (MPR) could serve as a
surrogate endpoint for survival and provide rapid means of comparing different neoadjuvant …

Background The response to neoadjuvant chemotherapy (NAC) differs substantially among
individual patients with non‐small cell lung cancer (NSCLC). Major pathological response …

Introduction Major pathologic response after neoadjuvant chemotherapy (NAC) for NSCLC
has been defined as 10% or less residual viable tumor without distinguishing between …

Pulmonary surfactants play a crucial role in managing lung lipid metabolism, and
dysregulation of this process is evident in various lung diseases. Alternations in lipid …

Neoadjuvant therapy is increasingly used to control local tumor spread and micrometastasis
of pancreatic ductal adenocarcinoma (PDAC). Pathology assessments of treatment effects …

Introduction Major pathologic response (MPR), defined as residual viable tumor of less than
or equal to 10%, currently serves as a surrogate end point for survival for patients with …

There is now growing evidence that the immune contexture influences cancer progression
and clinical outcome of patients with non-small cell lung cancer (NSCLC). If chemotherapy is …